Retractable Technologies

Retractable Technologies

Thomas J. Shaw founded Retractable Technologies in 1994 in Little Elm, Texas, after a career in medical-device design. The company grew out of his conviction that a mass-produced, automatically retracting syringe could reduce the needle-stick injuries that OSHA estimated infected thousands of health-care workers annually. Shaw remains majority owner and chief executive — an unusual dual role for a publicly traded medical-device manufacturer — with his family trust controlling roughly 58% of outstanding shares as of the most recent proxy (public record, 2024). Retractable Technologies operates a vertically integrated factory in Little Elm where it manufactures its core product lines: the VanishPoint syringe, blood-collection tubes, and IV catheters. The company derives virtually all revenue from safety-engineered sharps sold to U.S. acute-care hospitals and federal agencies, including a multiyear contract with the Department of Veterans Affairs. Its direct competitor is Becton Dickinson (BD), whose market share Retractable Technologies has contested through antidumping litigation — winning a series of patent-infringement verdicts against BD beginning in 2007 and most recently defending its 2024 trade-secret claims at the Federal Circuit. Total revenue for the twelve months ended September 2024 was approximately $36 million, per the company's SEC filings. Shaw employs roughly 150 people at the Texas facility and distributes product primarily through group purchasing organizations (GPOs) such as Premier and Vizient. The operating footprint is concentrated in North America, though limited sales into Latin America and the Middle East appear through third-party distributors. Retractable Technologies carried no long-term debt on its balance sheet in 2024 and held over $40 million in cash and marketable securities, per its Form 10-K — a deliberately conservative capital structure that Shaw has publicly discussed as a hedge against BD litigation cycles. In September 2024, the U.S. Court of Appeals for the Federal Circuit affirmed a lower-court ruling that preserved the company's ability to enforce its syringe-patent portfolio (per Reuters, September 2024). What distinguishes the firm structurally is Shaw's absolute control of both the board and the manufacturing process. Unlike most microcap medical-device companies that outsource production to contract manufacturers, Retractable Technologies builds its own assembly machinery, formulates its own plastics, and retains all tooling in-house. That vertical integration, combined with Shaw's refusal to accept dilution or sale, makes the company either a permanently independent niche competitor or a legacy bet on needle-stick regulation — depending on which institutional investor you ask.